A Long-Term Safety Study of MT-4666 in Patients With Mild to Moderate Alzheimer's Disease (AD)

Trial Profile

A Long-Term Safety Study of MT-4666 in Patients With Mild to Moderate Alzheimer's Disease (AD)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2015

At a glance

  • Drugs Encenicline (Primary) ; Acetylcholinesterase inhibitors
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 29 Sep 2015 Planned End Date changed from 1 Jan 2017 to 1 Oct 2015 as ClinicalTrials.gov record.
    • 29 Sep 2015 Planned primary completion date changed from 1 Jan 2017 to 1 Oct 2015 as per ClinicalTrials.gov record.
    • 05 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top